Memorial Sloan Kettering Partners with Quest for Cancer Dx | GenomeWeb

NEW YORK (GenomeWeb) – Memorial Sloan Kettering Cancer Center has partnered with Quest Diagnostics to use molecular testing of patients' tumors to provide better treatment options and understand the genomic underpinnings of the disease.

In the first phase of the collaboration, Memorial Sloan Kettering will provide contextual information about the mutations identified in a next-generation sequencing-based test developed by Quest and will contribute to the clinical annotation report provided to physicians.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.